FDA Recommends Removal of Voluntary Hold for Elevidys for Ambulatory Patients Post author:PacConAdmin Post published:July 28, 2025 Post category:Uncategorized FDA Recommends Removal of Voluntary Hold for Elevidys for Ambulatory Patients Source: FDA Press Releases Tags: aaps Read more articles Previous PostFDA Investigating Death of 8-Year-Old Boy Who Received Elevidys Next PostFDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers You Might Also Like FDA Finding of ER Lamotrigene Bioequivalence Opens Doors for More Generics August 4, 2023 FDA Increases Foreign CGMP Inspections in 2023 July 23, 2024 Quick Notes: Medical Device Clearances — April 18, 2024 April 18, 2024